Associate Director, Quantitative Pharmacology at Dyno Therapeutics

Waltham, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

PhD, PharmD, or equivalent training in Quantitative Pharmacology, Pharmaceutical Sciences, Engineering, Physics, Applied Mathematics, and/or Computational Sciences
8+ years of bio/pharma experience
Based in Waltham, MA (not remote)

Responsibilities

Provide strategies and plans for quantitative data analytics (pharmacometrics, population PK/PD analyses, mechanistic drug-disease modeling, meta-analyses, data mining), in alignment with Regulatory requirements as well as corporate and R&D goals, enabling advancement of Dyne programs across all stages of drug development
Provide expertise and guidance on quantitative aspects, including dosing strategies and PK/PD, to R&D program teams alongside Clinical Pharmacology and Biomarker Leads, collaborating with Medical, Biometrics, Pharmacovigilance, Preclinical Tox, and ADME/DMPK SMEs
Provide hands-on quantitative data analyses, including PK/PD modeling and related tools, supporting program pipeline progression from preclinical to clinical and early to late clinical development
Lead the department in establishing a fit-for-purpose internal PK/PD modeling workflow environment, from data inception to model building, qualifying, and simulations, enabling internal PK/PD analyses and interfacing with external modeling CROs
Identify and manage consultants and vendors to support M&S activities
Author high-quality regulatory documents
Ensure adherence to agreed timelines and budgets for execution of deliverables from Clinical Pharmacology studies and programs
Collaborate cross-functionally with all relevant areas to support corporate objectives

Skills

Key technologies and capabilities for this role

PharmacometricsPKPDQSPPBPKMechanistic ModelingData MiningQuantitative AnalyticsModeling and SimulationBiomarker Modeling

Questions & Answers

Common questions about this position

What is the salary for the Associate Director, Quantitative Pharmacology role?

This information is not specified in the job description.

Is this role remote or based in an office?

This role is based in Waltham, MA without the possibility of being a remote role.

What key skills are required for this position?

The role requires expertise in quantitative modeling including pharmacometrics, mechanistic PKPD, QSP, PBPK, population PK/PD analyses, mechanistic drug-disease modeling, meta-analyses, and data mining.

What is the company culture like at Dyne Therapeutics?

This information is not specified in the job description.

What makes a strong candidate for this role?

Strong candidates will have expertise in strategic planning and execution of pharmacology and biomarker-related modeling & simulation, hands-on quantitative data analyses, and the ability to collaborate seamlessly with cross-functional teams including Clinical Pharmacology, Biomarkers, Medical, Biometrics, and others.

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Watertown, MassachusettsHeadquarters

2018Year Founded

$106MTotal Funding

SERIES_ACompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.

Manufacturing bottlenecks could hinder scaling of Dyno's operations.

Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.

Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.

Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.

Collaboration with NVIDIA enhances biological sequence design for gene therapies.

Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free